Abstract
The clinical diagnosis and treatment of malignant bone tumors are still major clinical challenges due to their high incidence are difficulty. Targeted therapies have become a critical approach to treat bone tumors. In recent years, radiopharmaceuticals have been used widely and have shown potent and efficient results in treating bone tumors, among which (32)P and the labeled radiopharmaceuticals play an essential role. In this study, the (32)P-labeled hydroxyapatite (HA) was prepared through chemical synthesis ((32)P-Hap) and physical adsorption ((32)P-doped-Hap). The in vitro stability of (32)P-labeled HA was analyzed to assess the superiority of the new-found chemical synthesis. The radiolabeling yield and stability of chemical synthesis (97.6 ± 0.5%) were significantly improved compared with physical adsorption (92.7 ± 0.4%). Furthermore, the CT results corroborate that (32)P-Hap (100 μCi) +DOX group has the highest tumor suppression rate and can effectively reduce bone destruction. The results corroborate the effectiveness of the chemical synthesis and validate the application of (32)P-Hap in bone tumors. Therefore, (32)P-Hap (100 μCi) + DOX may be an effective strategy for bone metastasis treatments.